SG10201810449XA - Organoarsenic compounds and methods for the treatment of cancer - Google Patents
Organoarsenic compounds and methods for the treatment of cancerInfo
- Publication number
- SG10201810449XA SG10201810449XA SG10201810449XA SG10201810449XA SG10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- methods
- organoarsenic compounds
- organoarsenic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- JGDXFQORBMPJGR-YUMQZZPRSA-N (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(dimethylarsinothio)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CNC(=O)[C@H](CS[As](C)C)NC(=O)CC[C@H](N)C(O)=O JGDXFQORBMPJGR-YUMQZZPRSA-N 0.000 abstract 1
- KFYRJJBUHYILSO-UHFFFAOYSA-N 2-amino-3-dimethylarsanylsulfanyl-3-methylbutanoic acid Chemical compound C[As](C)SC(C)(C)C(N)C(O)=O KFYRJJBUHYILSO-UHFFFAOYSA-N 0.000 abstract 1
- PITSAYCDYJYBJS-UHFFFAOYSA-N 3-dipropylarsanylsulfanylpropane-1,2-diol Chemical compound CCC[As](CCC)SCC(O)CO PITSAYCDYJYBJS-UHFFFAOYSA-N 0.000 abstract 1
- IXIKZSYWGFDQQV-UHFFFAOYSA-N C[As](C)[S+]=C(CCC([O-])=O)O Chemical compound C[As](C)[S+]=C(CCC([O-])=O)O IXIKZSYWGFDQQV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 108700041071 darinaparsin Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18951108P | 2008-08-20 | 2008-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201810449XA true SG10201810449XA (en) | 2018-12-28 |
Family
ID=41707414
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201810449XA SG10201810449XA (en) | 2008-08-20 | 2009-08-14 | Organoarsenic compounds and methods for the treatment of cancer |
| SG10201810450QA SG10201810450QA (en) | 2008-08-20 | 2009-08-14 | Organoarsenic compounds and methods for the treatment of cancer |
| SG10201403869TA SG10201403869TA (en) | 2008-08-20 | 2009-08-14 | Organoarsenic compounds and methods for the treatment of cancer |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201810450QA SG10201810450QA (en) | 2008-08-20 | 2009-08-14 | Organoarsenic compounds and methods for the treatment of cancer |
| SG10201403869TA SG10201403869TA (en) | 2008-08-20 | 2009-08-14 | Organoarsenic compounds and methods for the treatment of cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20110269697A1 (enExample) |
| EP (2) | EP3388111B1 (enExample) |
| JP (5) | JP5933896B2 (enExample) |
| KR (3) | KR20180103194A (enExample) |
| CN (2) | CN104800828A (enExample) |
| AU (1) | AU2009282972A1 (enExample) |
| BR (1) | BRPI0918407A2 (enExample) |
| CA (1) | CA2734650A1 (enExample) |
| DK (2) | DK3388111T3 (enExample) |
| ES (2) | ES2901426T3 (enExample) |
| HK (1) | HK1212218A1 (enExample) |
| IL (1) | IL211153A0 (enExample) |
| MX (1) | MX2011001800A (enExample) |
| NZ (1) | NZ591181A (enExample) |
| PT (2) | PT3388111T (enExample) |
| RU (1) | RU2534606C2 (enExample) |
| SG (3) | SG10201810449XA (enExample) |
| WO (1) | WO2010021928A1 (enExample) |
| ZA (1) | ZA201101216B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085208A1 (en) * | 2013-12-05 | 2015-06-11 | Solasia Pharma K.K. | Compounds and methods for the treatment of cancer |
| CN104151397A (zh) * | 2014-07-03 | 2014-11-19 | 北京大学 | 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用 |
| JP6413969B2 (ja) * | 2015-07-29 | 2018-10-31 | 住友金属鉱山株式会社 | 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体 |
| WO2019220961A1 (ja) * | 2018-05-18 | 2019-11-21 | ソレイジア・ファーマ株式会社 | ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤 |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US234972A (en) | 1880-11-30 | William ennis | ||
| US761900A (en) | 1904-03-05 | 1904-06-07 | Newton Jefferson Norman | Flux compound. |
| US2349729A (en) | 1940-08-24 | 1944-05-23 | Parke Davis & Co | Therapeutic arsenic preparation |
| DK1391206T3 (da) | 1997-10-15 | 2008-09-01 | Polarx Biopharmaceuticals Inc | Farmaceutiske præparater der omfatter arsentrioxyd til behandling af ikke-Hodgkins lymfom |
| CA2309652C (en) | 1997-11-10 | 2013-01-29 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| WO2001080832A2 (en) | 2000-04-26 | 2001-11-01 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
| DE10132625A1 (de) | 2001-07-05 | 2003-01-23 | Oce Printing Systems Gmbh | Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten |
| EP2420229A1 (en) | 2002-01-07 | 2012-02-22 | Board Of Regents, University Of Texas System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| TW201440760A (zh) | 2004-07-16 | 2014-11-01 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| EP1919564B1 (en) | 2005-07-29 | 2014-11-26 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| CN104109177A (zh) * | 2006-01-13 | 2014-10-22 | 得克萨斯州A&M大学系统 | 用于治疗癌症的化合物和方法 |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
| CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| TW200914048A (en) * | 2007-07-17 | 2009-04-01 | Combinatorx Inc | Combinations for the treatment of B-cell proliferative disorders |
| JP2011502985A (ja) * | 2007-11-02 | 2011-01-27 | ジオファーム オンコロジー， インコーポレイテッド | 有機ヒ素剤を使用する併用療法 |
| US20100009934A1 (en) * | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
-
2009
- 2009-08-14 SG SG10201810449XA patent/SG10201810449XA/en unknown
- 2009-08-14 DK DK18174817.9T patent/DK3388111T3/da active
- 2009-08-14 DK DK09808635.8T patent/DK2321012T3/en active
- 2009-08-14 CA CA2734650A patent/CA2734650A1/en not_active Abandoned
- 2009-08-14 AU AU2009282972A patent/AU2009282972A1/en not_active Abandoned
- 2009-08-14 CN CN201410740427.5A patent/CN104800828A/zh active Pending
- 2009-08-14 KR KR1020187026317A patent/KR20180103194A/ko not_active Ceased
- 2009-08-14 JP JP2011523888A patent/JP5933896B2/ja active Active
- 2009-08-14 MX MX2011001800A patent/MX2011001800A/es not_active Application Discontinuation
- 2009-08-14 CN CN2009801356542A patent/CN102149432A/zh active Pending
- 2009-08-14 BR BRPI0918407A patent/BRPI0918407A2/pt not_active Application Discontinuation
- 2009-08-14 KR KR1020177024240A patent/KR20170103023A/ko not_active Ceased
- 2009-08-14 EP EP18174817.9A patent/EP3388111B1/en active Active
- 2009-08-14 SG SG10201810450QA patent/SG10201810450QA/en unknown
- 2009-08-14 ES ES18174817T patent/ES2901426T3/es active Active
- 2009-08-14 PT PT181748179T patent/PT3388111T/pt unknown
- 2009-08-14 EP EP09808635.8A patent/EP2321012B1/en active Active
- 2009-08-14 KR KR1020117006250A patent/KR20110058818A/ko not_active Ceased
- 2009-08-14 NZ NZ591181A patent/NZ591181A/xx not_active IP Right Cessation
- 2009-08-14 US US13/059,176 patent/US20110269697A1/en not_active Abandoned
- 2009-08-14 ES ES09808635T patent/ES2703740T3/es active Active
- 2009-08-14 PT PT09808635T patent/PT2321012T/pt unknown
- 2009-08-14 SG SG10201403869TA patent/SG10201403869TA/en unknown
- 2009-08-14 RU RU2011110392/14A patent/RU2534606C2/ru active
- 2009-08-14 WO PCT/US2009/053858 patent/WO2010021928A1/en not_active Ceased
-
2011
- 2011-02-10 IL IL211153A patent/IL211153A0/en unknown
- 2011-02-15 ZA ZA2011/01216A patent/ZA201101216B/en unknown
-
2014
- 2014-05-26 JP JP2014108079A patent/JP5976036B2/ja active Active
- 2014-10-27 US US14/524,586 patent/US10842769B2/en active Active
-
2015
- 2015-03-30 JP JP2015068284A patent/JP2015120755A/ja not_active Withdrawn
-
2016
- 2016-01-07 HK HK16100117.0A patent/HK1212218A1/xx unknown
- 2016-09-29 JP JP2016191062A patent/JP6315841B2/ja active Active
-
2017
- 2017-12-19 JP JP2017242759A patent/JP2018039853A/ja active Pending
-
2020
- 2020-10-15 US US17/071,435 patent/US11324713B2/en active Active
- 2020-10-15 US US17/071,623 patent/US11324714B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008079339A3 (en) | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| TW200744586A (en) | Therapeutic compounds | |
| WO2010093849A3 (en) | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | |
| MXPA05009694A (es) | Metodos para mejorar la calidad de la piel. | |
| SG10201810450QA (en) | Organoarsenic compounds and methods for the treatment of cancer | |
| NZ580226A (en) | Dimer compounds as inhibitors of iap | |
| WO2009026166A3 (en) | Antiinfective flavonol compounds and methods of use thereof | |
| MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| BRPI0413740A (pt) | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo | |
| NZ610378A (en) | Lipoyl compounds and their use for treating ischemic injury | |
| TW200510317A (en) | Caspase inhibitors and uses thereof | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| UA107562C2 (uk) | Спосіб лікування псоріазу | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| MY183063A (en) | Seed treatment agent and method for protecting plant | |
| TW200613308A (en) | Cyclobutanetetracarboxylate compound and preparation method thereof | |
| WO2004033423A3 (en) | Anticancer compounds | |
| IL165259A (en) | Compounds useful in the treatment of anthrax and inhibiting lethal factor | |
| ATE511835T1 (de) | Biophosphonate zur behandlung von endometriose | |
| TW200613292A (en) | Benzothiazolium compounds | |
| NZ591837A (en) | Amino acid derivative |